Skip to content
value.today

Affect Therapeutics, Inc.

Total raised
$25 M
2 rounds on record
Latest round
$18 M
Dec 2022
First round on record
Jun 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Affect Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$18 MNo. 2$10 to $50 million

Affect Therapeutics, Inc.: Raise no. 2, Dec 2022

Investors in this round

9 investors had bought by the notice of Jul 12, 2023: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kristin Muhlner · Executive Officer, Director
  • Jeff DeFlavio · Director
  • Jeff Rinehart · Director
  • Kevin Ryan · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold includes convertible notes and the securities issuable hereto.”

Signed by Kristin Muhlner, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 12, 2023. Read the notice at the SEC.

equitySEC
Jun 2021$7 MNo. 1$2 to $10 million

Affect Therapeutics, Inc.: Raise no. 1, Jun 2021

Investors in this round

10 investors had bought by the notice of Sep 23, 2021: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kristin Muhlner · Executive Officer, Director
  • Jeff DeFlavio · Director
  • Jeff Rinehart · Director
  • Kevin Ryan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold includes convertible notes and the securities issuable hereto.”

Signed by Kristin Muhlner, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 23, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Affect Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2023).

    SEC Form D · Jul 2023

  • The industry group it chose in its notices: Other.

    SEC Form D · Jul 2023

That is all the official record says: Affect Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Affect Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Affect Therapeutics, Inc.
NameRoleNamed in
Kristin MuhlnerExecutive officerJul 2023
Jeff DeFlavioDirectorJul 2023
Jeff RinehartDirectorJul 2023
Kevin RyanDirectorJul 2023
Kristin MuhlnerDirectorJul 2023
Stuart PetersonDirectorJul 2023